We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Cellartis and WARF Sign License Agreement for Human Embryonic Stem Cells
News

Cellartis and WARF Sign License Agreement for Human Embryonic Stem Cells

Cellartis and WARF Sign License Agreement for Human Embryonic Stem Cells
News

Cellartis and WARF Sign License Agreement for Human Embryonic Stem Cells

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Cellartis and WARF Sign License Agreement for Human Embryonic Stem Cells"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Cellartis AB and the Wisconsin Alumni Research Foundation (WARF), the private, nonprofit patenting and licensing organization for the University of Wisconsin-Madison, announced that they have signed a license for hES patents which enables Cellartis to commercialize undifferentiated hES cell products in the US.

"This is another significant and timely step forward for Cellartis and we are delighted to make this announcement," said Mats Lundwall, CEO.

"Our business is at an exciting point in its evolution as we broaden our range of products and drive growth through innovative collaborations. This license opens the door to the large and important US market, alongside additional emerging partnering opportunities in the US which fits well into our growth strategy,” Lundwall added.

"We are extremely pleased to announce our licensing agreement and welcome Cellartis as a new commercial partner," says Andy DeTienne, WARF's licensing manager for stem cell technologies.

"As a key provider of human embryonic stem cells and related products, we are pleased Cellartis is interested in entering the U.S. market. The expansion of Cellartis’ business strategy complements WARF’s goals for supporting growth in the human stem cell industry." He notes this licensing agreement with Cellartis reflects that commercial interest in human embryonic stem cells continues to be strong.
Advertisement